Crossmark Global Holdings Inc. Sells 910 Shares of Danaher Co. (NYSE:DHR)

Crossmark Global Holdings Inc. decreased its position in shares of Danaher Co. (NYSE:DHR) by 2.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,135 shares of the conglomerate’s stock after selling 910 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Danaher were worth $10,027,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Highview Capital Management LLC DE purchased a new stake in shares of Danaher during the 2nd quarter worth $781,000. Nations Financial Group Inc. IA ADV lifted its holdings in shares of Danaher by 9.4% during the 2nd quarter. Nations Financial Group Inc. IA ADV now owns 8,379 shares of the conglomerate’s stock valued at $2,094,000 after purchasing an additional 721 shares during the last quarter. Cortland Associates Inc. MO boosted its position in shares of Danaher by 0.4% in the 2nd quarter. Cortland Associates Inc. MO now owns 150,861 shares of the conglomerate’s stock worth $37,693,000 after purchasing an additional 538 shares in the last quarter. FAS Wealth Partners Inc. increased its position in Danaher by 6.5% during the 2nd quarter. FAS Wealth Partners Inc. now owns 7,558 shares of the conglomerate’s stock valued at $1,888,000 after buying an additional 459 shares in the last quarter. Finally, Ridgewood Investments LLC acquired a new stake in Danaher in the second quarter worth about $64,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by insiders.

Danaher Price Performance

NYSE DHR traded up $2.29 on Friday, hitting $269.31. The company had a trading volume of 4,595,672 shares, compared to its average volume of 2,803,002. The company has a market capitalization of $199.47 billion, a PE ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83. The company’s fifty day moving average price is $259.76 and its 200-day moving average price is $254.94. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.05 EPS. As a group, analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DHR shares. Jefferies Financial Group started coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Leerink Partners boosted their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Barclays boosted their price target on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Wells Fargo & Company began coverage on Danaher in a report on Tuesday. They set an “equal weight” rating and a $280.00 target price for the company. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.